Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease.
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Beijing, Kina, 100053
- Teva Investigational Site 03
-
Beijing, Kina, 100070
- Teva Investigational Site 02
-
Chengdu, Kina, 610041
- Teva Investigational Site 01
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD)
- Participants whose baseline total maximal chorea (TMC) score ≥ 8
- Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD
- Participants who have provided written consent for the use of personal and medical information for study purposes
Exclusion Criteria:
- Participants who have an unstable or serious medical or psychiatric illness at baseline
- Participants with any history of suicidality, untreated or inadequately treated depression
- Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias.
- Participants who received reserpine within 20 days of deutetrabenazine treatment initiation
- Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation
- Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation
- Participants unable to provide a written consent for the study.
- Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Deutetrabenazine
|
deutetrabenazine tablets
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in TMC Score in Participants Receiving ≥24 mg/Day
Tidsramme: Baseline, Week 16
|
The TMC score was determined from Item 12 of the motor assessment (Part 1) of the UHDRS and quantifies chorea (range, 0-28, lower score indicated less chorea).
It was the sum of maximal chorea scores for 7 body regions (face, buccal-oral-lingual, trunk, and 4 extremities), each of which was scored on a scale from 0 to 4 (0, absent; 1, slight or intermittent; 2, mild and common or moderate and intermittent; 3, moderate and common; and 4, marked and prolonged).
|
Baseline, Week 16
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Any Adverse Events (AEs) By Severity Grade
Tidsramme: Baseline up to Week 16
|
AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Severity of AEs recorded as one of following Common Terminology Criteria for Adverse Events (CTCAE) criteria: -Grade 1: Mild; asymptomatic or mild symptoms; clinical/diagnostic observations only; intervention not indicated.
-Grade 2: Moderate; local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL) (for example, preparing meals, shopping for groceries or clothes, using telephone).
-Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization; disabling; limiting self-care ADL (bathing, dressing, feeding self, using toilet, taking medications, and not bedridden).
-Grade 4: Life-threatening; urgent intervention indicated.
-Grade 5: Death related to AE.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With Serious Adverse Events (SAEs)
Tidsramme: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
The SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With Treatment-related AEs
Tidsramme: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Number of participants with treatment-related AEs is reported in this outcome measure.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs Leading to Dose Reduction, Interruption, Treatment Discontinuation, and Study Withdrawal
Tidsramme: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Number of participants with AEs leading to dose reduction, interruption, treatment discontinuation, and study withdrawal is reported in this outcome measure.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs in Titration Phase
Tidsramme: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs lasted from titration phase to maintenance phase were considered an AE that occurred in the titration phase.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs in Maintenance Phase
Tidsramme: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs of Special Interest
Tidsramme: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs of special interest included suicidality, depression, somnolence, QTc prolongation, akathisia, and parkinsonism.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Change From Baseline in TMC Score in All Participants Regardless of Study Drug Dose
Tidsramme: Baseline, Week 16
|
The TMC score was determined from Item 12 of the motor assessment (Part 1) of the UHDRS and quantifies chorea (range, 0-28, lower score indicated less chorea).
It was the sum of maximal chorea scores for 7 body regions (face, buccal-oral-lingual, trunk, and 4 extremities), each of which was scored on a scale from 0 to 4 (0, absent; 1, slight or intermittent; 2, mild and common or moderate and intermittent; 3, moderate and common; and 4, marked and prolonged).
|
Baseline, Week 16
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D LLC
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Nevrologiske manifestasjoner
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Psykiske lidelser
- Genetiske sykdommer, medfødte
- Nevrokognitive lidelser
- Kognisjonsforstyrrelser
- Demens
- Nevrodegenerative sykdommer
- Bevegelsesforstyrrelser
- Heredodegenerative lidelser, nervesystemet
- Basal ganglia sykdommer
- Dyskinesier
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Huntingtons sykdom
- Chorea
- Deutetrabenazine
Andre studie-ID-numre
Andre studie-ID-numre
- TV50717-NDG-40182
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .